Case Study: Biogen’s Leqembi Redefines Alzheimer’s Treatment Landscape: A Breakthrough in Disease Modification and Global Access
Case StudiesHeadquarters: Cambridge, Massachusetts, U.S.Offering: Leqembi (Lecanemab) – Amyloid Beta-directed Antibody Case Study Biogen Inc., a leading biotechnology company specializing in neurodegenerative and rare diseases, achieved a breakthrough in Alzheimer’s therapeutics through the global expansion of Leqembi (Lecanemab), its amyloid beta-directed antibody developed in collaboration with Eisai Co., Ltd. Following full approval by the U.S. Food […]